83 related articles for article (PubMed ID: 8993086)
1. Valproate as an antidepressant in major depressive disorder.
Davis LL; Kabel D; Patel D; Choate AD; Foslien-Nash C; Gurguis GN; Kramer GL; Petty F
Psychopharmacol Bull; 1996; 32(4):647-52. PubMed ID: 8993086
[TBL] [Abstract][Full Text] [Related]
2. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
Alpert JE; Franznick DA; Hollander SB; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
[TBL] [Abstract][Full Text] [Related]
3. Inositol augmentation of lithium or valproate for bipolar depression.
Eden Evins A; Demopulos C; Yovel I; Culhane M; Ogutha J; Grandin LD; Nierenberg AA; Sachs GS
Bipolar Disord; 2006 Apr; 8(2):168-74. PubMed ID: 16542187
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania.
Eden Evins A; Demopulos C; Nierenberg A; Culhane MA; Eisner L; Sachs G
Bipolar Disord; 2006 Feb; 8(1):75-80. PubMed ID: 16411983
[TBL] [Abstract][Full Text] [Related]
7. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression.
Zimmerman M; Posternak MA; Chelminski I
J Psychiatr Res; 2004; 38(6):577-82. PubMed ID: 15458853
[TBL] [Abstract][Full Text] [Related]
8. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
10. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
[TBL] [Abstract][Full Text] [Related]
11. An open trial of valproate in borderline personality disorder.
Stein DJ; Simeon D; Frenkel M; Islam MN; Hollander E
J Clin Psychiatry; 1995 Nov; 56(11):506-10. PubMed ID: 7592502
[TBL] [Abstract][Full Text] [Related]
12. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
Fava M; McCall WV; Krystal A; Wessel T; Rubens R; Caron J; Amato D; Roth T
Biol Psychiatry; 2006 Jun; 59(11):1052-60. PubMed ID: 16581036
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
Salloum IM; Cornelius JR; Daley DC; Kirisci L; Himmelhoch JM; Thase ME
Arch Gen Psychiatry; 2005 Jan; 62(1):37-45. PubMed ID: 15630071
[TBL] [Abstract][Full Text] [Related]
14. Factors that influence the outcome of placebo-controlled antidepressant clinical trials.
Niklson IA; Reimitz PE; Sennef C
Psychopharmacol Bull; 1997; 33(1):41-51. PubMed ID: 9133750
[TBL] [Abstract][Full Text] [Related]
15. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder.
Feiger AD; Heiser JF; Shrivastava RK; Weiss KJ; Smith WT; Sitsen JM; Gibertini M
J Clin Psychiatry; 2003 Mar; 64(3):243-9. PubMed ID: 12716264
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
[TBL] [Abstract][Full Text] [Related]
20. Response to desipramine treatment in adolescent major depression.
Boulos C; Kutcher S; Marton P; Simeon J; Ferguson B; Roberts N
Psychopharmacol Bull; 1991; 27(1):59-65. PubMed ID: 1862207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
